Key Drivers
- Strong Cash Flow
- Improving Margins
- Moderate Leverage
AIAI Summary
GRDN has shifted from a defensive healthcare distributor to an improving operator with real EBITDA leverage, but at ~38x earnings the stock now requires sustained, recurring margin expansion and clean execution to justify further upside, especially given the one-time settlement benefit and recent technical rollover.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong Cash Flow
- •Improving Margins
- •Moderate Leverage
GRDN is financially healthy with strong profitability, cash flow, and manageable leverage, but its rich valuation and sizeable intangibles temper the investment case.
Price Behavior
Key Price Behavior Insights:
- •Failed breakout
- •Near support
- •Weak momentum
GRDN has turned from range-bound to a short-term downtrend over the last month, with a failed breakout near $41-$44 and key support now at about $38.4.
Peak on 2026-08-07 followed by a steady drop into 2026-08-14 after losing prior range support
Sentiment & News
Key News Insights:
- •Revenue growth
- •EBITDA expansion
- •IRA pressure
Guardian Pharmacy Services delivered a solid Q2 with revenue up 2%, adjusted EBITDA up 19%, and raised full-year guidance, though IRA-related pricing pressure remains a margin headwind.
The results and raised outlook are modestly positive for GRDN, but ongoing policy-driven pricing pressure may cap near-term margin upside
Similar Companies in Healthcare
Other companies in the same sector with AI ratings